See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a novel anti-cancer drug that has been granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) [1]. While lurbinectedin has shown promising results in clinical trials, like all medications, it can have potential side effects.

According to the FDA's approval letter, common side effects of lurbinectedin include:

* Neutropenia, which is a decrease in the number of neutrophils, a type of white blood cell that fights infection [1].
* Anemia, or a decrease in red blood cells, which can lead to fatigue and shortness of breath [1].
* Leukopenia, a decrease in the number of white blood cells [1].
* Thrombocytopenia, a decrease in the number of platelets, which can lead to bleeding [1].
* Fatigue [1].
* Nausea [1].
* Diarrhea [1].
* Vomiting [1].
* Decreased appetite [1].
* Constipation [1].
* Increased liver enzymes [1].
* Musculoskeletal pain [1].
* Increased creatinine, a waste product that's produced by your muscles and removed from your body by your kidneys [1].

In addition to these common side effects, the FDA notes that lurbinectedin can cause serious side effects such as:

* Severe neutropenia, which can increase the risk of infection [1].
* Severe anemia, which can increase the risk of transfusion-related reactions [1].
* Severe thrombocytopenia, which can increase the risk of bleeding [1].
* Severe and fatal infections [1].
* Severe allergic reactions [1].
* QT prolongation, a heart rhythm disorder that can lead to serious heart problems [1].

It is important to note that the above-mentioned side effects are based on the FDA's approval letter and clinical trials, and individual experiences may vary. Patients should consult with their healthcare provider for a comprehensive understanding of the potential side effects of lurbinectedin treatment.

Sources:
[1] FDA. (2020). FDA approves lurbinectedin for metastatic small cell lung cancer. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lurbinectedin-metastatic-small-cell-lung-cancer>
[2] DrugPatentWatch. (n.d.). Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>